An Open Single-center Study in England to Assess Safety and Performance of a NIRS System to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- NEC
- Sponsor
- Carag AG
- Enrollment
- 50
- Primary Endpoint
- Performance of the CTOM system
- Status
- Not Yet Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
Preterm infants are highly vulnerable and may suffer from multiple life-threatening conditions that manifest low tissue oxygenation (StO2). Near infrared spectroscopy (NIRS) is a technique available to non-invasively and safely monitor the tissue oxygenation status (StO2), which can be beneficial or live saving for this fragile patient population. Unfortunately, traditional NIRS devices show a broad variability when applied to the abdomen (Bailey & Mally 2016). The novel device is designed especially for application of NIRS on the abdomen of preterm infants.
Detailed Description
Each child will be measured over a time span of three days with the novel NIRS device. 1. A two-hour measurement is performed in measurement phase 1 2. Additionally, the sensor will be placed five times onto the abdomen for 1-minute measurements, which constitutes measurement phase 2. 3. The final measurement phase 3 lasts for up to 70 hours. A total of two ultrasound (US) examination on the abdomen are performed during the first two measurement phases to assess the presence of air and stool in the abdomen. Additional assessment of SpO2 is performed throughout. Aside from the US and SpO2 measurement, no additional procedures will be performed. The NIRS measurement will not disturb necessary clinical and nursing procedures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Preterm infants with Gestational age less than 35 0/7 weeks
- •Signed Informed consent of the legal representative(s) is received after being informed. The consent form is signed by one legal representative, which is likely to be either the mother or the father. Only married fathers or those listed on the birth certificate are considered under UK regulations. In the case of non-married father, the mother must provide consent.
- •Clinically stable condition. The clinical stability is to be reconfirmed before the start and checked during the measurement.
Exclusion Criteria
- •Injured, hypersensitive or bruised skin present on the abdomen,
- •Existence of clinical instability at any time during the investigation leads to exclusion, if ordered so by the physician entrusted with the investigation,
- •Any medical care equipment, e.g. patches, dressing, umbilical arterial or venous catheter, blood supply, etc., prohibiting correct placement of the sensors,
- •Severe Congenital malformations,
- •Clinical abdominal concerns
- •Severe metabolic disorders,
- •Early onset sepsis,
- •Inability of legal representatives to understand the purpose of the clinical trial due to language barriers such as the insufficient ability to understand the spoken or written language,
- •The treatment of newborn jaundice with light during measurement time phase 1 and 2,
- •Previous enrolment into the current study,
Outcomes
Primary Outcomes
Performance of the CTOM system
Time Frame: 3 days
We intend to investigate sensor handling on preterm infants and record the signal variability and reproducibility. A measurement signal serves to analyse reproducibility, signal quality and different signal analysis methods. Abdominal oxygen tissue saturation will be calculated. The aStO2 values will be calculated with and without considering the presence of additional absorbers besides haemoglobin. The datasets to be analysed include three measurement series per subject from a total of at least 50 subjects. The planned analyses consist of descriptive statistics and time series analysis.
Secondary Outcomes
- Occurrence of adverse events is measured(3 days)